Growth Metrics

Aytu Biopharma (AYTU) Net Income (2016 - 2025)

Aytu Biopharma has reported Net Income over the past 15 years, most recently at $62000.0 for Q2 2025.

  • Quarterly Net Income rose 105.0% to $62000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $116000.0 through Dec 2025, up 108.7% year-over-year, with the annual reading at $620000.0 for FY2025, 118.65% up from the prior year.
  • Net Income was $62000.0 for Q2 2025 at Aytu Biopharma, up from $54000.0 in the prior quarter.
  • Over five years, Net Income peaked at $381000.0 in Q3 2024 and troughed at -$53.3 million in Q1 2022.
  • The 5-year median for Net Income is -$1.2 million (2024), against an average of -$8.7 million.
  • Year-over-year, Net Income crashed 546.8% in 2021 and then surged 158.89% in 2024.
  • A 5-year view of Net Income shows it stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 87.46% to -$839000.0 in 2023, then surged by 114.66% to $123000.0 in 2024, then crashed by 49.59% to $62000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Net Income are $62000.0 (Q2 2025), $54000.0 (Q1 2025), and $123000.0 (Q4 2024).